peptide 1 glp 1 Crystal structure of the GLP-1 receptor bound to a agonist Glucagon-like peptide-1: Trends in Endocrinology

About ATTAIN-MAINTAIN trial and ATTAIN clinical trial program ATTAIN-MAINTAIN (NCT06584916) was a 52-week, Phase 3, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of once-daily orforglipron versus placebo for maintenance of body weight reduction in adults with obesity or overweight with weight-related comorbidities who previously completed the SURMOUNT-5 head-to-head trial

Exp Biol Med (Maywood) 239(6):697

View Source THE LANCET 2023 Rosenstock J, et al

Headache in the first 1-2 doses sometimes attributed by community sources to vasodilatory effects

In line with this dedication, we are thrilled to announce the addition of two groundbreaking therapies to our repertoire: peptides, including BPC-157, and decompression therapy